Streetbeat News

Equity Actions

STZ

Constellation Brands, Inc. (NYSE:STZ) is expected to report Q3 earnings of $3.00 per share, up from $2.83 a year ago, with revenue estimated at $2.55 billion. The company also announced an additional $2 billion share repurchase authorization. Shares closed up 0.5% at $242.53. Analysts from Barclays, Wells Fargo, Goldman Sachs, Morgan Stanley, and B of A Securities have provided ratings and adjusted price targets for STZ.

Portfolio Pulse from Avi Kapoor

January 05, 2024 | 6:49 am

DYN

Dyne Therapeutics has announced the pricing of its public offering of 17.15 million shares of common stock at $17.50 per share, with expected gross proceeds of approximately $300.1 million. The offering is expected to close around January 9, 2024, with all shares being sold by Dyne.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 6:31 am

VYGR

Voyager Therapeutics has priced an underwritten public offering of 7,777,778 common shares at $9 each and pre-funded warrants for 3,333,333 shares at $8.999 each, aiming to raise approximately $100 million before fees and expenses. All securities are sold by the company.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 6:28 am

CPRX

Catalyst Pharmaceuticals has announced a public offering of $150M of its common stock, with an option for underwriters to purchase an additional 15% of the offered shares. The proceeds are intended for potential acquisition of new product candidates and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:52 pm

VERB

Verb Technology Company Inc (VERB) has entered into a Securities Purchase Agreement with Streeterville Capital, LLC, where Verb sold 3,000 shares of its newly designated non-convertible Series C Preferred Stock to Streeterville Capital for a total of $3 million, as disclosed in an 8-K filing.

Portfolio Pulse from Charles Gross

January 04, 2024 | 9:47 pm

NCPL

Lind Global Fund has disclosed a 9.9% ownership stake in Netcapital Inc. through a 13G filing, indicating a significant investment in the company.

Portfolio Pulse from Charles Gross

January 04, 2024 | 9:42 pm

PYPD

PolyPid Ltd. has announced a private placement of 3,371,312 shares at $4.81 per share, raising $16.2 million. The placement includes new and existing investors, with notable participation from DAFNA Capital Management and Rosalind Advisors. Investors also receive warrants to purchase additional shares at $5.50, which could bring in an extra $18.5 million if exercised in full. The warrants expire in two years or upon a positive outcome from the SHIELD II Phase 3 trial of D-PLEX100.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:34 pm

VYGR

Voyager Therapeutics' stock price is expected to decline after the company announced a proposed public offering of $100 million, which typically dilutes existing shareholders' equity.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:34 pm

ARKK

KRE

NVDA

TSLA

Matthew Tuttle, CEO of Tuttle Capital Management, has filed for six new leveraged and inverse Bitcoin ETFs. These ETFs are designed for short-term trading and are not recommended for non-active investors. Tuttle previously launched ETFs that bet against Cathie Wood's ARKK and Jim Cramer's stock recommendations. Additionally, Tuttle Capital launched leveraged and inverse ETFs for Tesla and NVIDIA in October 2023, with nearly $100 million in assets under management. Tuttle also introduced the SKRE ETF, which offers a leveraged inverse investment option against regional banks, following Cramer's recommendation of SVB Financial Group before its collapse.

Portfolio Pulse from Chris Katje

January 04, 2024 | 9:29 pm

ANY

Sphere 3D has sold its subsidiary HVE to its former President Joseph O'Daniel for a nominal amount, aligning with its shift towards the cryptocurrency sector. This transaction led to O'Daniel's resignation and a revised compensation agreement, as disclosed in an SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:25 pm